Advertisement
Advertisement
Dr. Axe Wire · Advanced therapies · health
Every Human BPC-157 Study So Far Reports Improvement With No Treatment Side Effects
A new review of all human research on the popular healing peptide BPC-157 found only three small studies and very low certainty of evidence.
A systematic review published October 8, 2026 in Acta Orthopaedica Belgica found that all three published human studies of BPC-157, the injury-recovery peptide, reported symptom improvement in most participants and no treatment-related side effects, across 30 people in total.
Researchers searched Embase, PubMed, the Cochrane Library and ClinicalTrials registry through June 1, 2026 and identified only three human studies meeting criteria for this PRISMA-compliant, PROSPERO-registered review. One retrospective study gave 16 people intra-articular (into-the-joint) BPC-157 injections for knee pain. A second retrospective pilot study gave 12 people BPC-157 instilled directly into the bladder for interstitial cystitis, a chronic bladder pain condition. A third prospective pilot study tested intravenous BPC-157 safety in 2 people. All three studies reported symptom improvement in most participants, and none reported treatment-related adverse events. Using the NIH quality tool for before-after studies without a control group, the authors judged all three studies poor in methodological quality and rated overall certainty of evidence very low due to serious risk of bias, indirect comparisons and imprecise results from the small sample sizes.
BPC-157 is marketed as a tissue-repair peptide, derived from a protein found in stomach juice, that proponents say speeds healing of tendons, ligaments and gut lining. The authors note it lacks regulatory approval for human use and that evidence has been largely limited to animal models. None of the three studies had a comparison group, which is why the authors call for larger, regulated trials to confirm the effect.
Advertisement
Review timeline for human BPC-157 evidence
- Database search cutoff (Embase, PubMed, Cochrane Library, ClinicalTrials.gov)
- Systematic review published in Acta Orthopaedica Belgica
With no control arm in any study, reported improvement cannot be separated from placebo response or the normal course of healing. The authors conclude the peptide needs ethically approved, regulated, high-quality clinical trials before any clinical use outside that setting.
Dr. Axe’s Take
Every human study of BPC-157 so far points the same way: people improved, and no one had a treatment-related side effect. That matches my own experience. After a major spinal injury left me in daily pain for ten months, BPC-157 and TB-500 turned things around within about a week. Add the deep animal research behind it, and I see this peptide as one of the most useful repair tools we have. The small numbers mean the big controlled trials haven't been run yet. If you want to try it for an injury or gut healing, work with a licensed practitioner who sources it properly (it isn't FDA-approved and is banned for tested athletes), keep up protein, bone broth, omega-3s and physical therapy, and don't change any prescribed medication without your doctor.
— Dr. AxeStory summary
- Who
- 30 total human participants across three studies: 16 with knee pain, 12 with interstitial cystitis, 2 in a safety study
- Design
- Systematic review (PRISMA-compliant, PROSPERO-registered) of retrospective and prospective pilot studies, searched through June 1, 2026
- Dose
- Intra-articular injection (knee study), intravesical instillation (bladder study), intravenous administration (safety study); specific doses not reported
- Primary result
- Symptom improvement reported in most participants across all three studies; no treatment-related adverse events reported
- Secondary
- Overall certainty of evidence rated very low due to serious risk of bias, indirectness and imprecision; all three studies judged poor methodological quality
- Funding / conflicts
- Funding and conflicts not reported in the abstract.
- Date
- Oct 8, 2026